Observational Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jul 26, 2025; 17(7): 106579
Published online Jul 26, 2025. doi: 10.4252/wjsc.v17.i7.106579
Recombinant human thrombopoietin safety and efficacy in pediatric allogeneic hematopoietic stem cell transplantation: A cohort study
Xue-Guo Li, Ru-Min Wang, Wei Chen, Tong Yao, Fen Chen, Yan-Fang Xu, Tao Lang
Xue-Guo Li, Ru-Min Wang, Yan-Fang Xu, Tao Lang, Department of Hematology, The People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, Xinjiang Uygur Autonomous Region, China
Wei Chen, Department of Blood Transfusion, The People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, Xinjiang Uygur Autonomous Region, China
Tong Yao, Fen Chen, Department of Pediatric Hematology, Children’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hospital of Beijing Children’s Hospital, Urumqi 830000, Xinjiang Uygur Autonomous Region, China
Co-first authors: Xue-Guo Li and Ru-Min Wang.
Author contributions: Li XG and Wang RM both contributed to drafting the initial manuscript; Li XG, Wang RM, Chen W, and Yao T designed and performed the research study; Chen F and Xu YF provided help and advice on experiments and analyzed the data; Lang T contributed equally to the conceptualization, supervision, and final manuscript revisions, justifying their corresponding author; All authors contributed significantly to the work and agreed to be accountable for all aspects of the work, contributed to editorial changes in the manuscript, and read and approved the final manuscript. Li XG and Wang RM are co-first authors who contributed equally to this work.
Institutional review board statement: This study was approved by the Ethics Committee of the People’s Hospital of the Xinjiang Uygur Autonomous Region (approval No. XJS2018080701).
Informed consent statement: Written informed consent was obtained from parents of all patients.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Data supporting the findings of this study are available from the corresponding author upon request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Lang, MD, Chief Physician, Department of Hematology, The People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Urumqi 830001, Xinjiang Uygur Autonomous Region, China. langt2024@163.com
Received: March 7, 2025
Revised: April 15, 2025
Accepted: June 25, 2025
Published online: July 26, 2025
Processing time: 139 Days and 2.1 Hours
Core Tip

Core Tip: This study evaluated the safety and efficacy of recombinant human thrombopoietin (rhTPO) in pediatric patients (0-17 years) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results show that rhTPO is well tolerated and improves platelet (PLT) recovery, with shorter PLT engraftment times in children (0-9 years) compared to adolescents (10-17 years). The incidence of acute graft-vs-host disease was higher in children but less severe. No severe adverse events related to rhTPO were observed, supporting its safety and utility in pediatric allo-HSCT. This study provides foundational insights for further research in larger pediatric cohorts.